Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2022-05-10 Earnings Release
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2022, reporting the company's financial results for the quarter ended March 31, 2022. It states that the financial results were announced via a press release attached as an exhibit. The document itself is a current report notifying the market of the earnings release but does not contain detailed financial statements or substantive financial data. The press release is furnished but not filed, and the 8-K serves as a notification of the earnings results. Given the nature of the document as an initial announcement of quarterly financial results, it fits the definition of an Earnings Release (ER). The document length is 3397 characters, which is consistent with a brief announcement rather than a full report. Therefore, the appropriate classification is ER with high confidence.
2022-05-10 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-28 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically reports the unregistered sale of equity securities due to conversion of preferred shares into common shares. It does not contain financial statements or detailed financial analysis, nor is it an earnings release or annual/interim report. The document is short (3172 characters) and focuses on a capital transaction event. Therefore, it fits best under Capital/Financing Update (CAP) category, which covers updates on company fundraising, financing activities, or capital structure changes.
2022-03-22 English
AMENDMENT NO. 12 TO THE SCHEDULE 13G
Major Shareholding Notification
2022-03-19 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-14 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.